Why Promising Pharmaceutical Technologies Stall between Laboratory Validation and Clinical Translation: A Failure-Mechanism Framework for Pharmaceutical Innovation

Promising pharmaceutical technologies frequently demonstrate reproducible technical performance under laboratory conditions yet fail to progress toward patient-relevant clinical use. Such attrition is often attributed to isolated scientific, regulatory, financial, or operational obstacles, obscuring the relationships through which weaknesses in one domain propagate across development. This Original Failure-Mechanism Framework Article proposes a multidimensional architecture for explaining translational stalls beyond technical performance. The framework distinguishes laboratory validation from translation readiness and organizes failure mechanisms into six interacting domains: reproducibility and model-system failure; mechanistic and biological-validity failure; manufacturing and quality-system failure; safety and pharmacological translation failure; clinical-workflow and implementation failure; and financing, coordination, and incentive misalignment. It further introduces three proposed constructs: the failure-mechanism profile, which represents the configuration of barriers affecting a technology; evidence debt, which arises when decision-critical assumptions remain unresolved across development transitions; and the translation observatory, a cross-functional mechanism for tracing evidence, uncertainty, and corrective action. Diagnostic indicators and corrective strategies are organized around claim specification, context of use, assumption exposure, falsification testing, and reassessment of decision readiness. The framework does not assign universal readiness scores or imply that satisfying one domain compensates for failure in another. Its relationships require retrospective evaluation in stalled programmes, prospective comparison across technology classes, inter-rater assessment, and testing of whether mechanism-based diagnosis improves decisions beyond existing development practices. The contribution is therefore a proposed conceptual synthesis for structured inquiry, not a validated predictive model, clinical recommendation, regulatory determination, or deployment-ready system.